Adma Biologics reported $53.66M in EBIT for its fiscal quarter ending in June of 2026.





Ebit Change Date
Adma Biologics USD 53.66M 5.57M Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Novavax USD 20.94M 100.32M Dec/2025
Omeros USD -48.15M 7.25M Sep/2023
Takeda JPY 205.32B 3.9B Sep/2026